Melanoma
Article
Which Patients Have the Best Chance With Checkpoint Inhibitors?
Are gene expression predictors the clue to determining which patients would benefit from checkpoint inhibitors? ...
News
Fatal toxicities from checkpoint inhibitors vary by agent
Cardiac and neurologic toxicities accounted for nearly half of all toxicities associated with cancer therapy with immune checkpoint inhibitors.
News
Nivolumab plus ipilimumab effective in melanoma brain metastases
Treatment with nivolumab plus ipilimumab resulted in clinically meaningful efficacy for melanoma patients with asymptomatic, previously untreated...
Audio
New Guidelines for Nonmelanoma Skin Cancer: What You Need to Know
Clinical Topics & News
Using Dermoscopy to Identify Melanoma and Improve Diagnostic Discrimination
Use of dermoscopy and detection algorithms by primary care physicians can enhance assessment of clinically suspicious lesions compared with that...
News
World Trade Center responders face greater cancer burden, including greater risk of multiple myeloma
The prevalence of multiple myeloma precursor disease was more than threefold higher in WTC exposed firefighters.
Clinical Topics & News
Nivolumab Linked to Nephritis in Melanoma
In this case report, researchers analyze a reoccurrence of kidney inflammation in a patient being treated for metastatic melanoma with...
Conference Coverage
Comorbidity and Survival With Receipt of Adjuvant Immunotherapy in Stage III Melanoma: An Analysis of the National Cancer Database
Abstract 5: 2017 AVAHO Meeting
Conference Coverage
Metabolic Reprogramming in BRAF Inhibitor-Resistant Melanoma Cells Leads to Hypersensitvity to Arginine Depletion and Upregulation of PD-L1 Expression
Abstract 36: 2017 AVAHO Meeting
Conference Coverage
Successful 3-Year Melanoma Treatment After Nivolumab Failure
Abstract 35: 2017 AVAHO Meeting
